

TABLE OF DELEGATION

On April 16, 2021, the shareholders met in a Combined General Shareholders' Meeting to determine the financial authorizations to be granted to the Board of Directors.

The current delegations are presented in the table below (their renewal will be proposed at the next General Meeting called to approve the financial statements for the year 2021):

Financial authorizations approved by the Combined General Shareholders' Meeting of April 16, 2021	Resolution	Period of validity from April 16, 2021	Maximum nominal amount	Maximum common nominal amount	Methods of determining the issue price	Use of the delegation
Delegation of authority to the Board of Directors to increase the share capital by issuance of ordinary shares or securities giving access to ordinary shares, to be issued immediately or in the future by the Company, with shareholders' preemptive subscription rights, in accordance with the provisions of Articles L. 225-129 and L. 22-10-49 et seq. of the French <i>Code de commerce</i> , and in particular Articles L. 225-129-2, L. 225-132 to L. 225-134, and Articles L. 228-91 et seq. of the French <i>Code de commerce</i>	Sixteenth resolution	26 months	Capital increase: EUR 260,000 Securities giving access to the capital to be issued: EUR 150,000,000	Capital increase: EUR 260,000 Securities giving access to the capital to be issued: EUR 150,000,000		None
Delegation of authority to the Board of Directors to increase the share capital by issuance of ordinary shares or securities giving access to ordinary shares, to be issued immediately or in the future by the Company, without shareholders' preemptive subscription rights, by way of public offerings, excluding offers referred to in article L. 411-2 1° of the French <i>Code monétaire et financier</i> , in accordance with the provisions of Articles L. 225-129 and L. 22-10-49 et seq. of the French <i>Code de commerce</i> , and in particular Articles L. 225-129-2, L. 22-10-51 and L. 22-10-52, and L. 228-91 et seq. of the French <i>Code de commerce</i>	Seventeenth resolution	26 months	Capital increase: EUR 230,000 Securities giving access to the capital to be issued: EUR 150,000,000	Securities giving access to the capital to be issued: EUR 150,000,000	Refer to (1) below	None

Financial authorizations approved by the Combined General Shareholders' Meeting of April 16, 2021	Resolution	Period of validity from April 16, 2021	Maximum nominal amount	Maximum common nominal amount	Methods of determining the issue price	Use of the delegation
Delegation of authority to the Board of Directors to increase the share capital by issuance of ordinary shares or securities giving access to ordinary shares, to be issued immediately or in the future by the Company, without shareholders' preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French <i>Code monétaire et financier</i> , in accordance with the provisions of Articles L. 225-129 et seq. and L. 22-10-49 of the French <i>Code de commerce</i> , and in particular Articles L. 225-129-2, L. 22-10-51 and L. 22-10-52, and L. 228-91 et seq. of the French <i>Code de commerce</i>	Eighteenth resolution	26 months	Capital increase: EUR 230,000 and up to the limit of 20% of the share capital per year Securities giving access to the capital to be issued: EUR 150,000,000		Refer to (1) below	None
Authorization to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders' preemptive rights, pursuant to the terms set by the General Shareholders' Meeting, and up to the limit of 10% of the share capital, in accordance with the provisions of Article L. 22-10-52 of the French <i>Code de commerce</i>	Nineteenth resolution	26 months	10% of the share capital for a period of 12 months to depart from May 28, 2020		Refer to (2) below	None

Financial authorizations approved by the Combined General Shareholders' Meeting of April 16, 2021	Resolution	Period of validity from April 16, 2021	Maximum nominal amount	Maximum common nominal amount	Methods of determining the issue price	Use of the delegation
Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders' preemptive subscription rights ¹ , in accordance with the provisions of Articles L. 225-129 et seq. and L. 22-10-49 of the French <i>Code de commerce</i> , and in particular Articles L. 225-129-2, L. 225-129-4, L. 22-10-51, L. 225-138, L. 228-91 et seq. of the French <i>Code de commerce</i>	Twentieth resolution	18 months	Capital increase: EUR 230,000 Securities giving access to the capital to be issued: EUR 150,000,000		Refer to (3) below	CEO's decision of 09/22/2021 on delegation of Board of Directors of 07/26/2021: issuance of 2,083,334 new shares CEO's decision of 09/29/2021 on delegation of Board of Directors of 07/26/2021: issuance of 130,856 new shares
Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders' preemptive subscription rights, in accordance with the provisions of Articles L. 225-135-1 and R. 225-118 of the French <i>Code de commerce</i>	Twenty-first resolution	26 months or 18 months (if used in the context of resolution 17)	15% of the initial issuance		Same price as the initial issuance	None

¹ The categories of beneficiaries must have one of the following characteristics: (i) natural or legal persons (including companies) trusts or investment funds, or other investment vehicles, in any form, established under French or foreign law, which regularly invest in the pharmaceutical, biotechnological or medical technology sectors; and/or (ii) companies, institutions or entities, in any form, French or foreign, exercising a significant part of its activities in the pharmaceutical, cosmetic or chemical sectors, or medical devices and/or technologies, or researching in such sectors; and/or (iii) French or foreign investment services companies, or any foreign establishment having an equivalent status, able to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above, and, in this context, to subscribe to the securities that are being issued.

Financial authorizations approved by the Combined General Shareholders' Meeting of April 16, 2021	Resolution	Period of validity from April 16, 2021	Maximum nominal amount	Maximum common nominal amount	Methods of determining the issue price	Use of the delegation
Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company, in accordance with the provisions of Articles L. 225-129 et seq. and L. 22-10-49 of the French <i>Code de commerce</i> , and in particular Articles L. 225-129-2, L. 22-10-54, and L. 228-91 et seq. of the French <i>Code de commerce</i>	Twenty-second resolution	26 months	Capital increase: EUR 230,000 Securities giving access to the capital to be issued: EUR 150,000,000			None
Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, in consideration for contributions in kind up to a maximum of 10% of the share capital, excluding the case of a public exchange offer initiated by the Company, in accordance with the provisions of Articles L. 225-129 et seq. and L. 22-10-49 of the French <i>Code de commerce</i> , and in particular Articles L. 225-129-2, L. 22-10-53, and L. 228-91 et seq. of the French <i>Code de commerce</i>	Twenty-third resolution	26 months	Capital increase: 10% of the share capital Securities giving access to the capital to be issued: EUR 150,000,000			None
Authorization to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums in accordance with the provisions of Articles L. 225-129-2 and L. 22-10-5 of the French <i>Code de commerce</i>	Twenty-fifth resolution	26 months	Capital increase: EUR 20,000			None

Financial authorizations approved by the Combined General Shareholders' Meeting of April 16, 2021	Resolution	Period of validity from April 16, 2021	Maximum nominal amount	Maximum common nominal amount	Methods of determining the issue price	Use of the delegation
Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers in accordance with the provisions of Articles L. 225-110-59 and L. 225-197-2 of the French <i>Code de commerce</i>	Twenty-sixth resolution	38 months	Capital increase: 5% of the share capital on the date of the Board of Directors' decision to grant them	Capital increase: EUR 260,000	N/A	Board of Directors of 04/16/2021: issuance of 466,000 free shares Board of Directors of 12/08/2021: issuance of 123,000 free shares
Authorization to the Board of Directors to grant share subscription and/or purchase options to corporate officers and employees of the Company or of companies in the group, entailing the waiver by the shareholders of their preemptive subscription rights to the shares issued as a result of the exercise of subscription options, in accordance with the provisions of Articles L. 225-177 et seq. and L. 22-10-56 of the French <i>Code de commerce</i>	Twenty-seventh resolution	38 months	Capital increase: 5% of the share capital on the date of the Board of Directors' decision to grant them		Refer to (5) below	None
Delegation of authority to the Board of Directors to decide on the issue of ordinary share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons ² , in accordance with the provisions of Articles L. 225-138, L. 225-129-2, L. 228-91 et seq. of the French <i>Code de commerce</i>	Twenty-eighth resolution	18 months	600,000 ordinary share subscription warrants Capital increase: EUR 6,000		Refer to (6) below	Board of Directors of 04/16/2021: issuance of 50,000 BSA

- (1) The issuance price will be determined as follows: (i) the issuance price of the shares to be issued under this resolution shall be at least equal to the minimum authorized by the legislation in force (to date, the weighted average of the prices of the last three trading days on the regulated market of Euronext Paris preceding the start of the public offer, which may be reduced by maximum discount of 10%) and (ii) the issue price of the securities to be issued under this resolution other than shares shall be such that the amount received

² Targeted categories: (i) executive employees or executive officers or members of the Company's management team who are not corporate officers, or (ii) members of the Board of Directors (including members of any research committee or those serving as censor) in office on the date of grant of the warrants, who are not executive officers of the Company or one of its subsidiaries, or consultants, managers or partners of companies providing services to the Company that have entered into a consulting or service agreement with the Company in force at the time of use of this delegation by the Board of Directors, or (iii) employees of the Company.

immediately by the Company plus, if applicable, the amount that may be received subsequently by the Company is, for each share issued as a result of the issue of these securities, at least equal to the amount mentioned in paragraph (i) above.

- (2) The Combined General Shareholders' Meeting of 16 April 2021 has delegated to the Board of Directors its authority to freely determine the issuance price of the securities, in accordance with the following conditions: (a) the issuance price will at least be equal: (i) either to the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading day preceding the pricing; (ii) or the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris over three consecutive trading days, chosen from the 30 trading days preceding the pricing date; which may be reduced by maximum discount of 15% and the Board of Directors may freely use any of the two formulas set forth above; and (b) for the securities to be issued pursuant to this resolution, other than ordinary shares of the Company, to an amount such that the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, i.e. for each ordinary share issued as a result of these securities being issued, is at least equal to the amount mentioned in paragraph (a) above.
- (3) the issuance price will at least be equal: (i) either to the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading day preceding the pricing; (ii) or the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris over three consecutive trading days, chosen from the 30 trading days preceding the pricing date; which may be reduced by maximum discount of 15% and the Board of Directors may freely use any of the two formulas set forth above, and for the securities to be issued pursuant to this resolution, other than ordinary shares of the Company, to an amount such that the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, i.e. for each ordinary share issued as a result of these securities being issued, is at least equal to the amount mentioned in paragraph (i) above.
- (4) The issue price(s) of the new shares or securities to be issued pursuant to this resolution shall be determined in accordance with the conditions set forth in Article L. 3332-19 of the French *Code du travail*, and decides to set the maximum discount of 20%. However, the Shareholders' General Meeting expressly authorizes the Board of Directors to reduce the discount or not to grant any discount, in particular to take account of the regulations applicable in the countries where the offer will be implemented.
- (5) The exercise price of the options granted under this resolution shall be set by the Board of Directors as follows (i) the exercise price of the of the share subscription option shall not be less than 80% of the average purchase price of the Company's shares on Euronext Paris regulated market during the twenty (20) trading sessions preceding the day on which the options are granted, and (ii) the exercise price of the share purchase options shall not be less than 80% of the average purchase price of the shares held by the Company pursuant to Article L.22-10-61 of the French *Code de commerce* or, as the case may be, of the share buyback program authorized by the 14th resolution submitted to this Meeting (i.e. that of 16 April 2021) pursuant to Article L.22-10-62 of the French *Code de commerce* or any share buyback program applicable previously or subsequently
- (6) The issuance price of a BSA 2021 shall be determined by the Board of Directors on the date of issue of said BSA 2021 according to the characteristics of the latter and shall in any event be at least equal to 8% of the market value of an ordinary share of the Company on the date of allocation of the BSA 2021, this market value corresponds to the volume-weighted average price of the last twenty (20) trading days preceding the date of grant of the BSA 2021 by the Board of Directors as long as the Company's shares are admitted to trading on the regulated market of Euronext Paris.